JP2021506813A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021506813A5 JP2021506813A5 JP2020532801A JP2020532801A JP2021506813A5 JP 2021506813 A5 JP2021506813 A5 JP 2021506813A5 JP 2020532801 A JP2020532801 A JP 2020532801A JP 2020532801 A JP2020532801 A JP 2020532801A JP 2021506813 A5 JP2021506813 A5 JP 2021506813A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- different
- substituted
- deuterium
- substituent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001424 substituent group Chemical group 0.000 claims 49
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 33
- 229910052805 deuterium Inorganic materials 0.000 claims 33
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 229910052794 bromium Inorganic materials 0.000 claims 20
- 229910052801 chlorine Inorganic materials 0.000 claims 20
- 229910052731 fluorine Inorganic materials 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- -1 juterium Inorganic materials 0.000 claims 5
- 206010028417 myasthenia gravis Diseases 0.000 claims 5
- 208000018360 neuromuscular disease Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 4
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 3
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- QNDGIHVLDAOMAJ-ZQCIBQAJSA-N (2R)-2-(4-bromo-2,6-dideuteriophenoxy)-3-fluoropropanoic acid Chemical compound BrC=1C=C(C(O[C@H](C(=O)O)CF)=C(C=1)[2H])[2H] QNDGIHVLDAOMAJ-ZQCIBQAJSA-N 0.000 claims 1
- QNDGIHVLDAOMAJ-RANRWVQCSA-N (2R)-2-(4-bromo-3,5-dideuteriophenoxy)-3-fluoropropanoic acid Chemical compound BrC1=C(C=C(O[C@H](C(=O)O)CF)C=C1[2H])[2H] QNDGIHVLDAOMAJ-RANRWVQCSA-N 0.000 claims 1
- QNDGIHVLDAOMAJ-ZXEPEWCSSA-N (2R)-2-(4-bromophenoxy)-2-deuterio-3-fluoropropanoic acid Chemical compound BrC1=CC=C(O[C@](C(=O)O)(CF)[2H])C=C1 QNDGIHVLDAOMAJ-ZXEPEWCSSA-N 0.000 claims 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
- YKUZRORDLPTRCX-QMMMGPOBSA-N BrC1=C(O[C@H](C(=O)O)CF)C=CC(=C1)Br Chemical compound BrC1=C(O[C@H](C(=O)O)CF)C=CC(=C1)Br YKUZRORDLPTRCX-QMMMGPOBSA-N 0.000 claims 1
- JCSMFQHKWJACCF-ZETCQYMHSA-N BrC1=CC(=C(O[C@H](C(=O)O)C(F)F)C=C1)F Chemical compound BrC1=CC(=C(O[C@H](C(=O)O)C(F)F)C=C1)F JCSMFQHKWJACCF-ZETCQYMHSA-N 0.000 claims 1
- CMNRIVFVSSSEQS-VIFPVBQESA-N BrC1=CC(=C(O[C@H](C(=O)O)CCF)C=C1)I Chemical compound BrC1=CC(=C(O[C@H](C(=O)O)CCF)C=C1)I CMNRIVFVSSSEQS-VIFPVBQESA-N 0.000 claims 1
- IYTOIGKTNSKCPJ-ANLVUFKYSA-N BrC1=CC(=C(O[C@H](C(=O)O)[C@@H](C)F)C=C1)F Chemical compound BrC1=CC(=C(O[C@H](C(=O)O)[C@@H](C)F)C=C1)F IYTOIGKTNSKCPJ-ANLVUFKYSA-N 0.000 claims 1
- QNDGIHVLDAOMAJ-QMMMGPOBSA-N BrC1=CC=C(O[C@H](C(=O)O)CF)C=C1 Chemical compound BrC1=CC=C(O[C@H](C(=O)O)CF)C=C1 QNDGIHVLDAOMAJ-QMMMGPOBSA-N 0.000 claims 1
- DCFQBPWASWEGTK-QMMMGPOBSA-N BrC1=CC=C(O[C@H](C(=O)O)CO)C=C1 Chemical compound BrC1=CC=C(O[C@H](C(=O)O)CO)C=C1 DCFQBPWASWEGTK-QMMMGPOBSA-N 0.000 claims 1
- JHHYBFHOOFFWKD-MUWHJKNJSA-N BrC1=CC=C(O[C@H](C(=O)O)[C@@H](C)F)C=C1 Chemical compound BrC1=CC=C(O[C@H](C(=O)O)[C@@H](C)F)C=C1 JHHYBFHOOFFWKD-MUWHJKNJSA-N 0.000 claims 1
- 102100023457 Chloride channel protein 1 Human genes 0.000 claims 1
- 101710091665 Chloride channel protein 1 Proteins 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- PGHBCHALFZYIDF-QMMMGPOBSA-N ClC1=CC(=C(O[C@H](C(=O)O)CF)C=C1)F Chemical compound ClC1=CC(=C(O[C@H](C(=O)O)CF)C=C1)F PGHBCHALFZYIDF-QMMMGPOBSA-N 0.000 claims 1
- GBFAYDMUUKCCAX-QMMMGPOBSA-N ClC1=CC=C(O[C@H](C(=O)O)CF)C=C1 Chemical compound ClC1=CC=C(O[C@H](C(=O)O)CF)C=C1 GBFAYDMUUKCCAX-QMMMGPOBSA-N 0.000 claims 1
- 208000004117 Congenital Myasthenic Syndromes Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 102000004310 Ion Channels Human genes 0.000 claims 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 206010029315 Neuromuscular blockade Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010066336 critical illness polyneuropathy Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 1
- 125000005816 fluoropropyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])* 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 239000000842 neuromuscular blocking agent Substances 0.000 claims 1
- 150000002923 oximes Chemical class 0.000 claims 1
- GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762598940P | 2017-12-14 | 2017-12-14 | |
| US62/598,940 | 2017-12-14 | ||
| EP18151605 | 2018-01-15 | ||
| EP18151605.5 | 2018-01-15 | ||
| PCT/EP2018/084980 WO2019115777A1 (en) | 2017-12-14 | 2018-12-14 | Phenoxy acids for the treatment of neuromuscular disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021506813A JP2021506813A (ja) | 2021-02-22 |
| JP2021506813A5 true JP2021506813A5 (https=) | 2022-01-06 |
Family
ID=64661403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020532801A Pending JP2021506813A (ja) | 2017-12-14 | 2018-12-14 | 神経筋障害の治療のためのフェノキシ酸 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3723745B1 (https=) |
| JP (1) | JP2021506813A (https=) |
| KR (1) | KR20200099146A (https=) |
| CN (1) | CN111587109A (https=) |
| AU (1) | AU2018382597B2 (https=) |
| CA (1) | CA3085226A1 (https=) |
| IL (1) | IL274744B2 (https=) |
| MX (1) | MX2020005398A (https=) |
| SG (1) | SG11202005359TA (https=) |
| TW (1) | TWI794369B (https=) |
| WO (1) | WO2019115777A1 (https=) |
| ZA (1) | ZA202002936B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021025637A2 (pt) * | 2019-06-19 | 2022-02-01 | Nmd Pharma As | Compostos para o tratamento de doenças neuromusculares |
| WO2024121130A1 (en) | 2022-12-05 | 2024-06-13 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| WO2024121129A1 (en) * | 2022-12-05 | 2024-06-13 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| EP4731200A1 (en) | 2023-06-20 | 2026-04-29 | NMD Pharma A/S | Clc-1 inhibitors for use in the treatment of multiple sclerosis and neuromuscular diseases |
| WO2025196206A1 (en) | 2024-03-20 | 2025-09-25 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1586463A (en) | 1976-08-02 | 1981-03-18 | Shell Int Research | Herbicidal compositions |
| KR100552133B1 (ko) * | 2002-06-26 | 2006-02-14 | 한국화학연구원 | 광학활성 (ｒ)-아릴옥시 프로피온산 에스터 유도체의제조방법 |
| SE0301009D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| GB0409921D0 (en) | 2004-05-04 | 2004-06-09 | Novartis Ag | Organic compounds |
| GB0422057D0 (en) | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
| EP2244711A4 (en) * | 2008-02-04 | 2011-08-24 | Cytokinetics Inc | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS |
| WO2012020567A1 (en) | 2010-08-09 | 2012-02-16 | Raqualia Pharma Inc. | Acyl piperazine derivatives as ttx-s blockers |
| MX389242B (es) * | 2015-06-15 | 2025-03-20 | Nmd Pharma As | Compuestos para su uso en el tratamiento de trastornos neuromusculares |
| TW201720437A (zh) * | 2015-10-29 | 2017-06-16 | 東北泰克諾亞奇股份有限公司 | 肌萎縮性疾病治療劑 |
-
2018
- 2018-12-13 TW TW107145015A patent/TWI794369B/zh active
- 2018-12-14 CA CA3085226A patent/CA3085226A1/en active Pending
- 2018-12-14 EP EP18815729.1A patent/EP3723745B1/en active Active
- 2018-12-14 MX MX2020005398A patent/MX2020005398A/es unknown
- 2018-12-14 KR KR1020207017872A patent/KR20200099146A/ko not_active Ceased
- 2018-12-14 SG SG11202005359TA patent/SG11202005359TA/en unknown
- 2018-12-14 AU AU2018382597A patent/AU2018382597B2/en active Active
- 2018-12-14 WO PCT/EP2018/084980 patent/WO2019115777A1/en not_active Ceased
- 2018-12-14 JP JP2020532801A patent/JP2021506813A/ja active Pending
- 2018-12-14 CN CN201880080205.1A patent/CN111587109A/zh active Pending
-
2020
- 2020-05-18 IL IL274744A patent/IL274744B2/en unknown
- 2020-05-20 ZA ZA2020/02936A patent/ZA202002936B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021506813A5 (https=) | ||
| IL274744B2 (en) | Phenoxy acids for the treatment of neuromuscular disorders | |
| Yates et al. | Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors | |
| Castro et al. | A new insight into pyrazinamide polymorphic forms and their thermodynamic relationships | |
| US10029994B2 (en) | Isoxazole hydroxamic acid compounds as LpxC inhibitors | |
| US8765812B2 (en) | Therapeutic compounds | |
| JP2016534134A5 (https=) | ||
| TW202208367A (zh) | 作為ｉｌ－１７調節劑之咪唑并嗒類 | |
| JP2008512380A5 (https=) | ||
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| JP2016500661A5 (https=) | ||
| JP2013056919A5 (https=) | ||
| NZ602435A (en) | Pyridine and pyrazine derivative for the treatment of cf | |
| JP2014532730A5 (ja) | オピオイド受容体の調節物質およびそれを含む薬学的組成物 | |
| JP2011523647A5 (https=) | ||
| JP6770511B2 (ja) | 心肺障害の処置のためのスフィンゴシン−１−リン酸受容体モジュレーター | |
| JP2017508794A5 (https=) | ||
| JP2021506787A5 (https=) | ||
| JP2016539174A5 (https=) | ||
| JP2010540569A5 (https=) | ||
| CA3046196A1 (en) | Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases | |
| JP2023531468A5 (https=) | ||
| Butcher et al. | 2-(2, 4-Dichlorophenyl)-N-(1, 5-dimethyl-3-oxo-2-phenyl-2, 3-dihydro-1H-pyrazol-4-yl) acetamide | |
| JP2022538541A5 (https=) | ||
| Zhong et al. | In vivo pharmacokinetic and pharmacodynamic profiles of orbifloxacin against Staphylococcus aureus in a neutropenic murine thigh infection model |